MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia

Basit Öğe Kaydı
dc.authoridNursal, Ayse Feyda / 0000-0001-7639-1122
dc.contributor.authorYurt, M.
dc.contributor.authorAyyildiz, O.
dc.contributor.authorKarakus, A.
dc.contributor.authorNursal, A. F.
dc.contributor.authorIsi, H.
dc.date.accessioned2021-11-01T15:03:12Z
dc.date.available2021-11-01T15:03:12Z
dc.date.issued2020
dc.department[Belirlenecek]
dc.description.abstractAIM: In 95 % of Chronic myeloid leukemia (CML) patients, chromosomal translocation resulting in the formation of the Philadelphia (Ph) chromosome (t:9;22) is observed, which in turn leads to the formation of the BCR-ABL fusion gene. MicroRNAs (miRNAs) are a group of small and non-coding RNAs modulating gene expression via binding to the target mRNAs. We aimed to characterize the expression profiles of various miRNAs in different stages of Ph(+) CML patients. METHODS: This case-controlled study was conducted in 75 CML patients and 25 healthy controls. The subjects were categorized into 4 groups; newly diagnosed patients, treatment-response patients, treatment-failure patients, and healthy controls. Expressions of miRNAs was analyzed by RT-PCR. RESULTS: miR-150 expression was downregulated in the treatment failure patients compared to the control group (p = 0.003212) while miRNA 148b expression up-regulated in the treatment failure patients than the control group (p = 0.038016). miR-10a expression was up-regulated in newly diagnosed and treatment response patients compared to control group (p = 0.003934, p = 0.000292, respectively). It was found that miR-10a expression increased 11.17- fold in newly diagnosed patients and 9.82-fold in treatment response patients than in the control group. CONCLUSION: Our data suggest that expression profiles of miR-10a, miR-150, and miRNA 148b were correlated as biomarker and therapeutic tool in Turkish patients with CML.
dc.identifier.doi10.4149/BLL_2020_023
dc.identifier.endpage163en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue2en_US
dc.identifier.pmid32115971
dc.identifier.scopus2-s2.0-85080840430
dc.identifier.scopusqualityQ2
dc.identifier.startpage159en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2020_023
dc.identifier.urihttps://hdl.handle.net/11491/7022
dc.identifier.volume121en_US
dc.identifier.wosWOS:000508930100011
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherComenius Univ
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectchronic myeloid leukemiaen_US
dc.subjectmicroRNAsen_US
dc.subjectnew diagnosisen_US
dc.subjecttreatment responseen_US
dc.subjecttreatment failureen_US
dc.titleMicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu